Targeted treatments for myelodysplastic syndrome (MDS).
| Mechanism of Action . | Therapeutic Compound . |
|---|---|
| Inhibition of mitochondria-mediated apoptosis | Erythropoietin, granulocyte colony-stimulating factor |
| Immunosuppression | Antithymocyte globulin, Cyclosporin A |
| Immune-modulation | Thalidomide, lenalidomide |
| Inhibitors of angiogenesis | VEGF inhibitors |
| DNA hypomethylation | Azacytidine, decitabine |
| Inhibition of histone deacetylation | Valproic acid, depsipeptide, MS275 |
| Oncogenee deactivation | Farnesyl trransferase inhibitors, imatinib |
| Enzyme and kinase inhibition | TLK199, Src family kinase inhibitors |
| Mechanism of Action . | Therapeutic Compound . |
|---|---|
| Inhibition of mitochondria-mediated apoptosis | Erythropoietin, granulocyte colony-stimulating factor |
| Immunosuppression | Antithymocyte globulin, Cyclosporin A |
| Immune-modulation | Thalidomide, lenalidomide |
| Inhibitors of angiogenesis | VEGF inhibitors |
| DNA hypomethylation | Azacytidine, decitabine |
| Inhibition of histone deacetylation | Valproic acid, depsipeptide, MS275 |
| Oncogenee deactivation | Farnesyl trransferase inhibitors, imatinib |
| Enzyme and kinase inhibition | TLK199, Src family kinase inhibitors |